6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2024

Commission File Number: 001-41641

SHL TELEMEDICINE LTD.

 (Translation of registrant’s name into English)

90 Yigal Alon Street

Tel Aviv 67891, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧             Form 40-F ☐

EXPLANATORY NOTE

On April 17, 2024, SHL Telemedicine Ltd. (the “Company”) issued a press release and an investor presentation with respect to its 2023 annual results, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein. In addition, on the same day the Company filed with the SIX Swiss Exchange its Annual Report to shareholders for the year ended December 31, 2023 (the “Report”), which contains audited consolidated financial statements as of and for the year ended December 31, 2023. A copy of the Report is attached hereto as Exhibit 99.3 and is incorporated by reference herein. The press release, investor presentation and Report contain forward-looking statements and include cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statements.

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 9, 2023 (Registration No. 333-272546).

Exhibit	Description
99.1	Press release, dated April 17, 2024, with respect to 2023 annual results.
99.2	Investor Presentation issued on April 17, 2024, with respect to 2023 annual results.
99.3	Annual Report to shareholders for the year ended December 31, 2023, filed with the SIX Swiss Exchange.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SHL Telemedicine Ltd.
By:	/s/ Amir Hai
	Amir Hai
	Chief Financial Officer

April 17, 2024

EX-99.1

Exhibit 99.1

Press release

Ad hoc announcement pursuant to Art. 53 LR

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

TEL AVIV & ZURICH & NEW YORK, April 17, 2024 - SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation.

In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL’s Israel operation maintained stability and profitability, reflecting the company's solid foundation in its home market. In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart^® ECG platform, enhancing access to remote cardiac care. Additionally, the launch of virtual visit services in Germany, in collaboration with BARMER, marked a significant expansion of SHL's offerings, further demonstrating the company's innovative approach to telemedicine and its commitment to broadening healthcare accessibility.

FY2023 Financial Highlights:
*All comparable previous periods figures are in constant currency¹.

• Total revenues rose to USD 57.1m, a 3.1% increase from USD 55.4m in 2022.

• Revenues from the Company's operation in Israel increased by 2.3% compared to 2022, with revenues standing at USD 42.1m.

• Revenues from the Company's operation in Germany amounted to USD 14.1m, a 2.4% increase from USD 13.7m in 2022.

• Adjusted EBITDA² for the Company was USD 2.1m, compared to USD 3.5m in 2022, mainly due to increased investment in Germany and in USA as well as non-recurring expenses of USD 2.2m, related to onetime and restructuring expenses of USD 1.6m in Germany and USD 0.6m Nasdaq® listing expenses.

• Cash on hand and short-term cash investments as of December 31, 2023, remain robust at USD 26m.

• Net loss was USD 6.9m, compared to a net loss of USD 0.4m in 2022. The decrease is mainly related to a lower operating profit and to financial expenses due to investor options modifications, which is a non cash item.

¹ Constant currency – to enable meaningful comparison between 2023 and 2022 results, 2022 results are also presented at 2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.

² Please see the EBITDA, Adjusted EBITDA and Adjusted EBIT Table below, and Reconciliation Table of Adjusted EBITDA and Adjusted EBIT to net profit each presented below as required by the rules of the U.S. Securities and Exchange Commission with respect to non-GAAP financial measures.

Strategic Developments and Highlights:

• In the United States, SHL made significant strides in its direct-to-consumer strategy, prioritizing promotion of its SmartHeart^® ECG technology. Concurrently, SHL continues to leverage its Tier1 strategic customer relationships, including the integration within CVS Minute Clinics, underscoring SmartHeart^®'s increasing acceptance in the healthcare ecosystem.

• In 2023, clinical studies from Mayo Clinic and the Imperial College London showcased SmartHeart^®'s unique promise to reduce emergency visits and readmission rates for cardiac patients. The final TELE-ACS findings from Imperial College London study presented at ACC24 and published in JACC, revealed groundbreaking results including a 76% reduction in hospital readmissions and a 41% decrease in ED visits, validating SHL's unique offering in remote cardiac care.

• SHL's SmartHeart^® technology also excelled in the U.S. Army's Project Convergence – Capstone 4 experiment, showcasing its reliability and advancing military healthcare.

• In Israel, SHL's B2C and B2B activities saw growth, with revenues increasing by 2.3% to $42.1m. Despite challenges caused by the war that broke out in the beginning of the 4^th quarter, Israel remains highly profitable for SHL.

• In Germany, the Doctors' Virtual Visit service launched with BARMER is now available to 12.4 million insured individuals. With a strong growth trend, it's expected to be a key driver for reaching break-even in German operations.

Looking ahead to 2024, the Company expects to see continued growth in revenues with double-digit growth in profitability in their Israel operations; continued consistent growth in the Virtual Visits service in Germany alongside the German operation reaching break even in 2024 and profitability during 2025; Moreover, the company expects to benefit from the investments previously made in the US, both in B2B and B2C activities.

Erez Nachtomy, CEO of SHL, remarked: "The results from 2023 reflect our strategic approach towards stable growth and financial stability amidst the dynamic market landscape. Our achievements in Israel, the advancement of our Virtual Visit services in Germany, and our focused investments in the US market provide the fundament for further growth. Our commitment remains steadfast on driving growth, enhancing financial stability, and meeting our strategic milestones, all while delivering value to our customersand stakeholders and leading the charge in the telemedicine landscape."

Conference Call 4 pm CET / 10 am ET / 5 pm Israel Time
The conference call can be accessed live via the below dial-in numbers:

From Europe	+41 (0)58 310 50 00
From the UK	+44 (0) 207 107 06 13
From the USA	+1 (1) 631 570 56 13
From Israel	+972 3763 1173
Toll free:	1 80 921 44 27
Local:	+972 3763 1173

Other international numbers are available here.

After the presentation, there will be an open Q&A. The conference call is scheduled to last 40-60 minutes and will be held in English.

The presentation is available on: www.shl-telemedicine.com/reports
The Full-Year Report 2023 is available on: www.shl-telemedicine.com/reports
SEC submission of the Full-Year Report and presentation is available on:
https://www.shl-telemedicine.com/sec-filing/

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.

Financial calendar
May 9, 2024, Special General Meeting. Tel Aviv, Israel

For more financial information:
For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for applicable periods, please visit the Company’s profile at https://www.sec.gov/edgar or the Company’s full report on its site: www.shl-telemedicine.com/reports

Key Figures for 2023

Key figures (as reported):

in USD million (except per share amounts)	2023	2022	% change
Revenues for the period	57.1	59.0	(3.3)
Revenues
Revenues •          Germany •          Israel •          Rest of the World	14.1 42.1 0.9	13.4 45.1 0.5	5.2 (6.8) 88.0
EBIT	(9.0)	(5.2)	(74.3)
EBITDA*	(1.3)	2.0
Net profit (loss)	(6.9)	0.2
EPS (Basic loss)	(0.43)	(0.01)
Operating cash flow	(1.5)	(0.1)

* EBITDA: operating profit excluding depreciation and amortization expenses of USD 7.7 m, and USD 7.1 m in the comparable period

Adjusted key figures (in constant currency):

In the table below, 2022 results have been presented at 2023 exchange rates. Management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.

In USD million	2023	2022	% change
Revenues	57.1	55.4	3.1
Revenues •          Germany •          Israel •          Rest of the World	14.1 42.1 0.9	13.7 41.1 0.5	2.4 2.3 88.0
Adjusted EBIT**	(5.6)	(3.3)
Adjusted EBITDA ***	2.1	3.5

**Adjusted EBIT: Please see the EBITDA, Adjusted EBITDA and Adjusted EBIT Table below.

***Adjusted EBITDA: Please see the EBITDA, Adjusted EBITDA and Adjusted EBIT Table below.

EBITDA, Adjusted EBITDA and Adjusted EBIT Tables (2022 results are presented in 2023 exchange rates)

EBITDA:
in USD Thousand	2023	2022
Operating loss	(9,006)	(5,336)
Plus:
Depreciation and amortization expenses	7,692	6,813
EBITDA	(1,314)	1,477
	2023	2022
Operating loss – EBIT	(9,006)	(5,336)
Plus:
Cost of share-based payments	1,252	1,601
Non-recurring expenses	2,198	397
Adjusted EBIT	(5,556)	(3,338)

in USD Thousand	2023	2022
EBITDA	(1,314)	1,477
Plus:
Cost of share based payments	1,252	1,601
Non-recurring expenses	2,198	397
Adjusted EBITDA	2,136	3,475

Reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities and Exchange Commission with respect to non-GAAP financial measures (2022 results are presented also in 2023 exchange rates)

in USD Thousand	2023	2022	2022(CC)
Net profit (loss)	(6,855)	215	(439)
Financial income, net	3,042	6,477	5,900
Tax expenses	891	1,097	1,003
Depreciation and amortization expenses	7,692	7,134	6,813
EBITDA	(1,314)	1,969	1,477
Cost of share-based payment	1,252	1,757	1,601
Non- recurring expenses	2,198	416	397
Adjusted EBITDA	2,136	4,142	3,475

The Company believes Adjusted EBITDA and Adjusted EBIT provide useful information regarding the Company’s financial and operating performance.  Adjusted EBITDA and Adjusted EBIT are not U.S. GAAP measures.  You should not construe Adjusted EBITDA and Adjusted EBIT as alternatives to operating profit or cash flows from operating activities determined in accordance with U.S. GAAP or as a measure of liquidity.  Adjusted EBITDA and Adjusted EBIT are not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies.

Forward Looking Statements:
This announcement contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements, including, the Company’s anticipation with respect to changes in its results of operations from prior periods. Readers are cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from historical results or any future results expressed or implied by forward-looking statements. Factors that can cause actual results to differ from expectations and those contained in forward-looking statements include those risks described in Item 3.D. "Key Information—Risk Factors" contained in the Company’s Registration Statement on Form 20-F filed with the U.S. Securities Exchange Commission (the "SEC") on March 28, 2023 and in its subsequent filings and submissions with the SEC, including, but not limited to, the Company’s ability to operate and comply with the complex and evolving regulations in the highly regulated healthcare industry; the continued development, consumer acceptance and market adoption of the Company’s products and services in the relatively new, unproven and volatile and rapidly changing telehealth market; the Company’s ability to develop and introduce new products and solutions and enhancements to existing ones; the significant and increasing levels of competition in the telemedicine market; the impacts of COVID-19 and future pandemics and epidemics; the Company’s ability to continue to attract and retain key employees and personal in the highly competitive healthcare industry; the loss or breach of the Company’s proprietary rights and data security and privacy risks; political, judicial, legal, economic and military conditions in Israel and the surrounding region; global economic and financial market conditions and the Company’s ability to adapt to and comply with the different business and market factors, conditions, requirements and laws and regulations in the various countries in which the Company operates internationally; currency fluctuations; labor disputes; the Company’s ability to manage growth and integrate acquired businesses and expanding operations; the Company’s ability to obtain adequate levels of insurance to cover potential losses; the Company’s dependence on key suppliers and sub-contractors and other third parties; and other matters and risks not yet known to the Company or not currently considered material by it. You should not place undue reliance on these forward-looking statements. All written and oral forward-looking statements, attributable to  the Company, or persons acting on its behalf, are qualified in their entirety by these cautionary statements. Unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements.

For further information please contact:
Fabienne Farner, IRF, Phone: +41 43 244 81 42, farner@irf-reputation.ch

EX-99.2

Exhibit 99.2

 SHL Telemedicine  Yearly Investor Presentation  2023 

 2  מידע צופה פני עתיד  Forward looking statements  This presentation was prepared for the purpose of providing and presenting information in a summary only and cannot replace a review of the reports of SHL Telemedicine (hereinafter: "the Company"). Many of the statements included in this presentation, as well as oral statements that may be made by us or by officers, directors or employees acting on behalf of us, contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from historical results or any future results expressed or implied by forward-looking statements. Factors that can cause actual results to differ from expectations and those contained in forward-looking statements include those risks described in Item 3.D. “Key Information—Risk Factors” contained in the Company’s Registration Statement on Form 20-F or most recent Annual Report on Form 20-F filed with the U.S. Securities Exchange Commission (the “SEC”) and in its subsequent filings and submissions with the SEC, including, but not limited to, the Company’s ability to operate and comply with the complex and evolving regulations in the highly regulated healthcare industry; continued development, consumer acceptance and market adoption in the relatively new, unproven and volatile and rapidly changing telehealth market; the Company’s ability to develop and introduce new products and solutions and enhancements to existing ones; the significant and increasing levels of competition in the telemedicine market; the impacts of COVID-19 and future pandemics and epidemics; the Company’s ability to continue to attract and retain key employees and personal in the highly competitive healthcare industry; the loss or breach of the Company’s proprietary rights and data security and privacy risks; political, judicial, legal, economic and military conditions in Israel and the surrounding region; global economic and financial market conditions and the Company’s ability to adapt to and comply with the different business and market factors, conditions, requirements and laws and regulations in the various countries in which the Company operates internationally; currency fluctuations; labor disputes; the Company’s ability to manage growth and integrate acquired businesses and expanding operations; the Company’s ability to obtain adequate levels of insurance to cover potential losses; the Company’s dependence on key suppliers and sub-contractors and other third parties; and other matters and risks not yet known to the Company or not currently considered material by it. You should not place undue reliance on these forward-looking statements. All written and oral forward-looking statements, attributable to the Company, or persons acting on its behalf, are qualified in their entirety by these cautionary statements.  For the avoidance of doubt, it is clarified that the company does not undertake to update the information, in whole or in part, contained in this presentation, whether as a result of new information, a future event or for other reasons, except as required by law. It is also clarified that the company's plans and strategy contained in this presentation are correct at the time of their publication and can and will change in accordance with the decisions of the company's board of directors, as they will be from time to time, and/or due to their being dependent, in whole or in part, on third parties that are not under the control of the company as well as on additional risk factors to which the company is exposed .  This presentation contains trade names, trademarks and service marks of other companies. The trade names, trademarks, and service marks of other parties are not used or displayed to imply a relationship with, or endorsement or sponsorship of, those other parties. 

 SHL Telemedicine At a Glance  3  Active in 2 Models:   B2B & B2C  Active in 3 Territories  Over 30 years of experience and data aggregated  $57.1M  Revenues in 2023  Unique Portable, 12-lead ECG technology SmartHeart ® Platform  Nasdaq: SHLT  SWX: SHLTN  Traded on NASDAQ and in Switzerland  SHL is a leader in the development and provision of advanced telemedicine technologies and services  *Compared to FY2022 in Constant currency – to enable meaningful comparison between FY2023 and FY2022 results, FY2022 results are also presented at FY2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.  +3.1%(*) 

 FY2023 Financial Data Overview  4  (*) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures  (**) Constant currency – to enable meaningful comparison between FY2023 and FY2022 results, FY2022 results are also presented at FY2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.  Operational Cash Flow  $(1.5)M  Adjusted EBITDA(*)  $2.1M  Revenues  $57.1M  Cash on Hand  ~$26M  Gross Profit  $25.3M 44% of revenues  Net Loss  $(6.9)M  Germany  Revenue: $14.1M +2.4% Compared to FY2022cc(**)  USA  Revenue: $0.9M +88%  Compared to FY2022cc(**)  Israel  Revenue: $42.1M +2.3% Compared to FY2022cc(**)  Revenue Growth in all Territories  in Constant Currency(**) 

 Operational Overview Active in 3 Territories, B2B & B2C  5  Germany  USA  Israel  SHL Telemedicine  SHL B2C  SHL B2B  Chronic  B2B  Telehealth  B2B   SmartHeart  B2B Sales  SmartHeart  B2C Sales  Providing advanced medical services to large institutional customers in Israel, through Mediton  Advanced B2C telemedicine services, selling cardiac monitoring services to consumers with 24/7 medical center and intensive care mobile units in coverage areas  Telemedicine services in a B2B model with leading Health Insurers. Management and stabilization of chronic patients including geriatric patients, saving costs for insurers   Advanced remote medical services, including Virtual Visit services. Agreements with leading health insurers in Germany to save costs. New agreement for 7 years with BARMER  Marketing and distribution of SmartHeart platform via B2B channels, such as CVS chain, medical device distributors, hospitals etc  Initiated marketing and distribution of SmartHeart DTC membership program, through online sales 

 Looking Ahead 2024 Outlook  6  Israel  Germany  USA  Accumulating meaningful operational data for optimizing sales strategy  Significant advancements in major B2B sales channel  Continued growth in Virtual Visits services  Advancing operational efficiency towards break even, with the goal of achieving profitability in 2025  Expecting double digit growth in revenues and profits   Launch of new products in B2C activity   Implementing hybrid B2B medical services - combining onsite and mobile services  Expecting improvement in operational efficiency including reduction in expenses with achievement of commercial goals 

 Israel Activity  Advanced B2C Telemedicine Services  Advanced B2B Medical Services  

 Israel Activity 2023 Results Summary  8  SHL Leads in B2C Telemedicine  Advanced B2B Medical Services  Selling cardiac monitoring services to the end customer: a 12-lead personal ECG device for remote medical data transfer, a 24/7 medical center, and intensive care mobility in coverage areas  Over 100 institutional clients - Mediton Group is a leading provider of B2B healthcare services in Israel to the largest and leading companies in Israel, government institutions, the Ministry of Defense, National Insurance, health funds and insurance companies  (*) Constant currency – to enable meaningful comparison between FY2023 and FY2021-22 results, FY2021-22 results are also presented at FY2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.  (**) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures  Key growth engines for 2024:  Increasing the number of subscribers  Implementation of cross sales between SHL and Mediton  Leveraging the platform and reputation to add synergistic services and products to customers  Acquisitions in the company's fields of activity or in tangential fields  Telemedicine hotline  A network of 500+ specialist doctors  4 advanced medical centers  Customer Support Hotline  Intensive care ambulance unites with extensive coverage areas  FY2023  FY2022  REVENUES  $42.1M  ADJUSTED EBITDA(**)  $11.4M  REVENUES(*)  $41.1M  $11.5M  ADJUSTED EBITDA(**)(*)  Robust performance and continued industry leadership despite the war in Gaza 

 Israeli Activity Key Annual Operating Data   800,000  Contacts with the telemedicine center  18,000   Tests performed at the medical centers  Over 23,000  Ambulances Alerted  1,500,000  Online data transmissions from end user devices to the medical center  315,000   Contact with customer service center  33,000   Virtual doctor visits  23,000   Physical doctor visits  9 

 10  B2C activity in Israel -   strong & leading brand in the field of telemedicine services   SHL operates a professional medical center for remote guidance and treatment around the clock offering advanced intensive care mobile units.  50,000Subscribers  $40 Average per subscriber / month  6 years average per subscriber  Over 150,000 devices in the subscriber homes  SHL telemedicine subscribers utilize the SHL ECG technology, including its advanced SmartHeart ECG  B2B activity in Israel - advanced medical services (Mediton)  Providing various medical services to institutional clients in order to receive an indication of the medical status of various subjects, verify compliance with various medical standards, provide preventive medicine and diagnostic medicine.  400  Employees  Over 500 Specialist Doctors  4 advanced medical centers  Mediton is a significant growth engine SHL’s Israel Operation   ~100 leading institutional clients  Cross Selling 

 Germany Activity 

 SHL Germany Telemedicine Services  12  Remote medicine services such as Virtual Visit and treatment of chronic patients, are becoming the Standard of Care  The company has agreements with leading health insurers covering about 30% of the German health insurance market (about 25 million insured)  SHL is the market leader in Germany and operates in a B2B model - management and stabilization of chronic patients and cost savings for health insurers - Fixed Fee Per Patient.  FY2023  FY2022  REVENUES  $14.1M  ADJUSTED EBITDA(**)  $(0.2)M  REVENUES(*)  $13.7M  $(0.3)M  ADJUSTED EBITDA(**)(*)  (*) Constant currency – to enable meaningful comparison between FY2023 and FY2021-22 results, FY2021-22 results are also presented at FY2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.  (**) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures  Chronic  Telehealth  German Insurance Providers  Revenue based on a Fixed Fee Per Patient  Revenue based on a Pay Per Use Model  Management and Stabilization of Chronic Patients  Remote Medical Services  B2B  Model 

 13  Germany Virtual Visits Service  Penetrating a market of about 800 million annual physical doctor visits  The virtual visit service is already available to 12.4 million BARMER and AOK PLUS insureds throughout Germany  Consistent Growth since Launch in April 2023  VIRTUAL VISITS  (*) https://www.statista.com/statistics/236512/annual-doctor-visits-per-capita-in-germany-since-1991/  Regulatory Drivers in 2024  No limitation on the extent of virtual visits  Allowing physicians to treat patients from home   In Germany - an average of 10 physical visits per person to a doctor each year (*)  

 USA Activity  SHL USA 

 USA   15  B2C plan: focus on direct-to-consumer sales of the SmartHeart® ECG  Tier1 Strategic customers relationships strengthening our reputation in support of the SmartHeart® direct-to-consumer move  Leveraging our network of cardiologists that is already set up across the US  REVENUES FY23  $0.9M  REVENUES FY22  $0.5M  The Platform   B2B  Model  B2C  Model  Agreements with Hospitals  Agreement with CVS  Successful Participant in a US Army Evaluation  Online - private subscription to SmartHeart service 

 USA   Established a robust strategy in 2023 that prioritizes direct-to-consumer sales of SmartHeart®  16   “With a focus on remote cardiac care, SHL Telemedicine harnesses the power of digital tools to bring life-saving services directly to patients, regardless of their location.”  Establishing Go To Market Strategy   and building market presence  

 USA   17  Mayo Clinic HELP MI   Telemedicine group compliant users vs. control group   Imperial College London TELE-ACS Study   Telemedicine group vs. control standard care group at 3 months follow-up  Presented at ACC24 Late-Breaking Clinical Trial Sessions Accepted for publication in the Journal of the American College of Cardiology(*)  Presented at VPM 23  Reduction  in “any ED Hospitalization”  Reduction  in “any ED visit”  CV ED visitor Hospitalization  43%  ZERO  33%  Reduction  in hospital readmission   Reduction  in ED attendance   76%  41%  (*) https://www.jacc.org/doi/10.1016/j.jacc.2024.03.398  Outstanding full results from Imperial College study - Presented at ACC24 Promising Initial Results in Mayo Clinic study  The results translate into significant cost savings for hospitals in readmissions  A very compelling business model for hospitals to use the SmartHeart platform 

 Financials  Selected data from P&L statements,   balance sheet and cash flow 

 Financials - P&L*  19  (*) compared to FY 2022 in constant currency, Please see Supplemental Information at end of presentation for a description of the basis of presentation of the constant currency amount calculations as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures  (**) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures  Revenues  In USD million   In USD million (except per share amounts)  FY2023  FY2022cc*  Revenues for the period  57.1  55.4  Revenues by territories  Germany  14.1  13.7  Israel  42.1  41.1  Rest of the World  0.9  0.5  Adjusted EBIT(**)  (5.6)  (3.3)  Adjusted EBITDA(**)  2.1  3.5  Net loss  (6.9)  (0.4) 

 Financials - Balance Sheet and Cashflow  20  Total cash and short-term investments  In USD million   In USD million   FY 2023  FY 2022  Cash and cash equivalents  6.7  4.5  Short term investments  19.6  14.2  Total cash and short-term investments  26.3  18.7  Short term bank debt  2.2  2.2  Long term bank debt  10.5  13.0  Total bank debt  12.7  15.2  Capital and reserves   153.6  128.8  Accumulated deficit  (80.1)  (73.1)  Total Equity  73.5  55.7  Increase (Decrease) in cash and short-term investments  7.6  (13.4)  Operational cash flow  (1.5)  (0.1) 

 Thanks  SHL Telemedicine 

 22  Supplemental Information  *Numbers are rounded up.  **Adjusted EBIT: Please see the Adjusted EBITDA and Adjusted EBIT Table below.  ***Adjusted EBITDA: Please see the Adjusted EBITDA and Adjusted EBIT Table below  In the table below, FY 2022 results have been presented at FY 2023 exchange rates1. Management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.  Adjusted key figures (in constant currency1)*  in USD million  FY2023  FY2022cc  % change  Revenues   57.1  55.4  3.1  Revenues   Germany  Israel  Rest of the World  14.1  13.7  2.4  42.1  41.1  2.3  0.9  0.5  88.5  Adjusted EBIT**  (5.6)  (3.3)  Adjusted EBITDA ***  2.1  3.5  Key figures (as reported):*  in USD million  (except per share amounts)  FY2023  FY2022  % change  Revenues for the period  57.1  59.0  (3.3)  Revenues  Revenues   Germany  Israel  Rest of the World  14.1  13.4  (5.2)  42.1  45.1  (6.8)  0.9  0.5  88.5  EBIT  (9.0)  (5.2)  EBITDA  (1.3)  2.0  Net profit (loss)  (6.9)  0.2        Operating cash flow  (1.5)  (0.1)     Reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures 

 23  Supplemental Information  (1) Constant currency – to enable meaningful comparison between FY2023 and FY2022 results, FY2022 results are also presented at FY2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.  *Numbers are rounded up.  Reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures (FY2022 results are presented also in FY2023 exchange rates1)  The Company believes Adjusted EBITDA and Adjusted EBIT provide useful information regarding the Company’s financial and operating performance. Adjusted EBITDA and Adjusted EBIT are not IFRS or U.S. GAAP measures. You should not construe Adjusted EBITDA and Adjusted EBIT as alternatives to operating profit or cash flows from operating activities determined in accordance with IFRS or U.S. GAAP or as a measure of liquidity. Adjusted EBITDA and Adjusted EBIT are not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies  in USD million*  FY2023  2022(CC1)  FY2022  Net profit (loss)  (6.9)  (0.4)  0.2  Financial income net  (3.0)  (5.9)  (6.5)  Tax expenses  0.9  1.0  1.1  Depreciation and amortization expenses  7.7  6.8  7.1  EBITDA  (1.3)  1.5  2.0  Share-based compensation  1.3  1.6  1.8  Non- recurring expenses  2.2  0.4  0.4  Adjusted EBITDA  2.1  3.5  4.1